Postpartum Glucose Testing, Related Factors and Progression to Abnormal Glucose Tolerance in a Rural Population with a Known History of Gestational Diabetes
Overview
Affiliations
Aims: Gestational diabetes is a strong risk factor for postpartum progression to glucose intolerance. The aims of the study were to determine rate of postpartum glucose testing , its related factors and rate of progression to glucose intolerance in women who underwent postpartum glucose testing after pregnancy that complicated by gestational diabetes.
Materials: this is a retrospective study and women with gestational diabetes who received prenatal care during 2005-2015 in 3 rural health centers of Khuramshahr (southwestern of Iran) were enrolled. Gestational diabetes mellitus diagnosed by FPG test only, 75g OGTT or GCT. The American Diabetes Association(ADA) criteria applied for definition of postpartum glucose intolerance (pre-diabetes or diabetes) .
Results: Mean duration of follow-up was 29.7 months. BMI≥ 25 was detected in 73.3% and 78.7% of women during pre-pregnancy and postpartum respectively. Overall 45.8% (60/131) of women received postpartum glucose testing. Rate of progression to abnormal glucose tolerance was 23.3% (8.5% pre-diabetes and 15.2% diabetes). Advanced maternal age was associated with postpartum glucose testing (OR 1.066, CI 1.008-1.128, p=0.02).
Discussion: high rate of overweight and obesity, sub optimal rate of postpartum glucose testing and high prevalence of glucose intolerance, highlights the importance of postpartum screening with a more sensitive test and implementation of an intervention program to prevent type 2 diabetes in rural population particularly older women with prior gestational diabetes.
Gu Y, Chen Y, Hu L, Chen S, Wang L, Chen M Arch Gynecol Obstet. 2025; .
PMID: 39873768 DOI: 10.1007/s00404-025-07953-4.
Tavakoli N, Nafissi N, Shokri S, Fallahpour M, Soleimani S, Riahi T Med J Islam Repub Iran. 2023; 37:15.
PMID: 37123336 PMC: 10134091. DOI: 10.47176/mjiri.37.15.
Shivashri C, Hannah W, Deepa M, Ghebremichael-Weldeselassie Y, Anjana R, Uma R PLoS One. 2022; 17(12):e0278919.
PMID: 36508451 PMC: 9744276. DOI: 10.1371/journal.pone.0278919.
Manoharan N, Jayaseelan V, Kar S, Jha N Indian J Endocrinol Metab. 2022; 26(4):319-327.
PMID: 36185952 PMC: 9519841. DOI: 10.4103/ijem.ijem_164_22.
Lai F, Li Z, Yue S, Pei L, Xiao H, Li Z Lipids Health Dis. 2021; 20(1):91.
PMID: 34429117 PMC: 8386098. DOI: 10.1186/s12944-021-01519-4.